Market news: Novo Nordisk (NVO.N) announced a collaboration with biopharmaceutical company Vivtex to jointly develop next-generation oral treatments for obesity and diabetes. Vivtex will be eligible for up to $2.1 billion, plus royalties from future net sales of the products.